Electrocardiographic Abnormalities and QTc Prolongation in Lupus Patients on Hydroxychloroquine in Tehran, Iran
Novelty in Biomedicine,
Vol. 13 No. 3 (2025),
27 July 2025
,
Page 179-183
https://doi.org/10.22037/nbm.v13i3.47828
Abstract
Background: Hydroxychloroquine, a commonly prescribed treatment for systemic lupus erythematosus (SLE), has been associated with potential cardiac complications, including QTc prolongation. QTc prolongation increases the risk of arrhythmias and sudden cardiac death. This study aimed to evaluate electrocardiographic (ECG) abnormalities in Iranian SLE patients receiving hydroxychloroquine treatment.
Materials and Methods: A cross-sectional study was conducted at the rheumatology clinic of Imam Hossein Hospital in Tehran, Iran. The study included patients diagnosed with systemic lupus erythematosus (SLE) receiving hydroxychloroquine treatment. Demographic and clinical data were collected through patient interviews and medical records. All participants underwent a 12-lead electrocardiogram (ECG), and the QT interval was corrected using the Bazett formula. QTc prolongation was defined as QTc≥450 ms. Additionally, fragmented QRS complexes, premature ventricular contractions (PVCs), and other ECG abnormalities were recorded.
Results: A total of 81 SLE patients on hydroxychloroquine were analyzed. The mean age was 48.5 years, and the average QTc interval was 426.52 ms (SD: 28.82 ms). QTc prolongation was observed in 16.05% of cases. Fragmented QRS complexes were found in the inferior, and V1-V3 leads in several patients, while no right or left bundle branch blocks (RBBB or LBBB) were detected. Three patients presented with PVCs, and one case showed a Brugada pattern.
Conclusion: QTc prolongation and fragmented QRS complexes were identified in many SLE patients treated with hydroxychloroquine. Regular ECG monitoring may be necessary for early detection of potential cardiac risks in this population.
- Systemic lupus erythematosus
- Hydroxychloroquine
- QTc prolongation
- Electrocardiographic abnormalities
- Fragmented QRS
- Premature ventricular contractions
- Iran
How to Cite
References
Siegel, C.H. and L.R. Sammaritano, Systemic lupus erythematosus: a review. Jama, 2024. 331(17): p. 1480-1491.
Barber, M.R., et al., Global epidemiology of systemic lupus erythematosus. Nature Reviews Rheumatology, 2021. 17(9): p. 515-532.
Yafasova, A., et al., Long-term cardiovascular outcomes in systemic lupus erythematosus. Journal of the American College of Cardiology, 2021. 77(14): p. 1717-1727.
Bello, N., et al., Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis. Lupus, 2023. 32(3): p. 325-341.
Dima, A., et al., Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Therapeutic advances in musculoskeletal disease, 2022. 14: p. 1759720X211073001.
Grimaldi, L., et al., Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus. JAMA network open, 2024. 7(8): p. e2432190-e2432190.
Petri, M., et al., Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis & Rheumatology, 2021. 73(6): p. 997-1004.
Han, J., et al., The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling. Biomedicine & Pharmacotherapy, 2020. 132: p. 110848.
Kyburz, D., F. Brentano, and S. Gay, Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling. Nature clinical practice Rheumatology, 2006. 2(9): p. 458-459.
Nirk, E.L., F. Reggiori, and M. Mauthe, Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO molecular medicine, 2020. 12(8): p. e12476.
Joyce, E., A. Fabre, and N. Mahon, Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. European Heart Journal: Acute Cardiovascular Care, 2013. 2(1): p. 77-83.
Dey, S., et al., Hydroxychloroquine and cardiotoxicity. Cardiology in Review, 2023: p. 10.1097.
Chatre, C., et al., Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug safety, 2018. 41: p. 919-931.
Farhat, H., et al., Hydroxychloroquine and the associated risk of arrhythmias. Global Cardiology Science & Practice, 2024. 2024(2): p. e202417.
Nazarenko, N., et al., A series of hydroxychloroquine-associated cardiotoxicity presenting with heart failure. Annals of Medicine and Surgery, 2025: p. 10.1097.
Zhang, Y.-H. and S. Babaeizadeh, Synthesis of standard 12‑lead electrocardiograms using two-dimensional generative adversarial networks. Journal of Electrocardiology, 2021. 69: p. 6-14.
Rovenský, J. and J. Payer, Systemic lupus erythematosus disease activity index (SLEDAI). Dictionary of Rheumatology. Springer Vienna, Vienna, 2009: p. 209-209.
Dahlberg, P., et al., QT correction using Bazett’s formula remains preferable in long QT syndrome type 1 and 2. Annals of Noninvasive Electrocardiology, 2021. 26(1): p. e12804.
O’Laughlin, J.P., P.H. Mehta, and B.C. Wong, Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Reports in Cardiology, 2016. 2016(1): p. 4626279.
Nishiyama, T., et al., QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine. Modern Rheumatology, 2021. 31(6): p. 1107-1112.
Hosonuma, M., et al., Fragmented QRS complex in patients with systemic lupus erythematosus at the time of diagnosis and its relationship with disease activity. PloS one, 2020. 15(1): p. e0227022.
Tselios, K. and M.B. Urowitz, Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. Current rheumatology reviews, 2017. 13(3): p. 206-218.
- Abstract Viewed: 113 times
- pdf Downloaded: 91 times